Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: Final results from the Phase 2 open-label extension study

被引：0
|
作者：
Ferrante, M. [1 ]
Feagan, B. G. [2 ]
Panes, J. [3 ]
Baert, F. [4 ]
Louis, E. [5 ,6 ]
Dewit, O. [7 ]
Kaser, A. [8 ]
Duan, W. R. [9 ]
Gustafson, D. [10 ]
Liao, X. [11 ]
Wallace, K. [10 ]
Kalabic, J. [12 ]
D'Haens, G. R. [13 ]
机构：
[1] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[2] Univ Western Ontario, Clin Trials Design & Management, London, ON, Canada
[3] Hosp Clin Barcelona, Dept Inflammatory Dis, Barcelona, Spain
[4] AZ Delta, Dept Gastroenterol, Roeselare Menen, Belgium
[5] Univ Liege, Dept Gastroenterol, Liege, Belgium
[6] CHU Liege, Liege, Belgium
[7] Clin Univ St Luc, Dept Gastroenterol, Brussels, Belgium
[8] Univ Cambridge, Dept Gastroenterol, Cambridge, England
[9] AbbVie Inc, Dept Pharmacovigilance & Patient Safety, N Chicago, IL USA
[10] AbbVie Inc, Dept Immunol, N Chicago, IL USA
[11] AbbVie Inc, Dept Data & Stat Sci, N Chicago, IL USA
[12] AbbVie Deutschland GmbH & Co KG, Dept Immunol, Ludwigshafen, Germany
[13] Univ Amsterdam, Med Ctr, Dept Gastroenterol, Amsterdam, Netherlands
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
MODERATE;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OP27
引用
收藏
页码：S024 / S025
页数：2
相关论文
共 50 条
  • [1] LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE: FINAL RESULTS FROM THE PHASE 2 OPEN-LABEL EXTENSION STUDY
    Ferrante, Marc
    Feagan, Brian G.
    Panes, Julian
    Baert, Filip J.
    Louis, Edouard
    Dewit, Olivier
    Kaser, Arthur
    Duan, Weijiang
    Gustafson, Dawn
    Liao, Xiaomei
    Wallace, Kori
    Kalabic, Jasmina
    D'Haens, Geert R.
    GASTROENTEROLOGY, 2020, 158 (06) : S1198 - S1198
  • [2] Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study
    Ferrante, Marc
    Feagan, Brian G.
    Panes, Julian
    Baert, Filip
    Louis, Edouard
    Dewit, Olivier
    Kaser, Arthur
    Duan, W. Rachel
    Pang, Yinuo
    Lee, Wan-Ju
    Gustafson, Dawn
    Liao, Xiaomei
    Wallace, Kori
    Kalabic, Jasmina
    D'Haens, Geert R.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (12): : 2001 - 2010
  • [3] INTERIM LONG-TERM SAFETY/EFFICACY OF RISANKIZUMAB TREATMENT IN CROHN'S DISEASE PATIENTS FROM THE OPEN-LABEL EXTENSION STUDY
    Ferrante, M.
    Panes, J.
    Baert, F.
    Louis, E.
    Kaser, A.
    Gustafson, D.
    Hall, D.
    Boecher, W. O.
    Herichova, I.
    Liao, X.
    Wallace, K.
    Kalabic, J.
    D'Haens, G.
    GUT, 2019, 68 : A64 - A64
  • [4] Long-Term Safety and Efficacy of Risankizumab Treatment in Patients With Crohn's Disease: 3-Year Interim Results From the Ongoing Phase 2 Open-Label Extension Study
    Ferrante, Marc
    Feagan, Brian G.
    Panes, Julian
    Baert, Filip
    Louis, Edouard
    Dewit, Olivier
    Kaser, Arthur
    Duan, Weijiang
    Gustafson, Dawn
    Liao, Xiaomei
    Wallace, Kori
    Kalabic, Jasmina
    D'Haens, Geert R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S466 - S466
  • [5] Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease With 3 Years of Treatment: Results From the FORTIFY Open-Label Long-Term Extension
    Ferrante, M.
    Panaccione, R.
    Colombel, J. F.
    Dubinsky, M. C.
    Hisamatsu, T.
    Lindsay, J. O.
    Song, A.
    Yao, Y.
    Zhang, Y.
    Zambrano, J.
    Aponte, F.
    Duan, W. R.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i109 - i111
  • [6] Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension
    Ferrante, M.
    Panaccione, R.
    Colombel, J. F.
    Dubinsky, M.
    Hisamatsu, T.
    Lindsay, J. O.
    Song, A.
    Neimark, E.
    Zhang, Y.
    Kligys, K.
    Crowley, J.
    Duan, W. R.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I167 - I169
  • [7] EFFICACY AND SAFETY UP TO THREE YEARS OF RISANKIZUMAB TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE FORTIFY OPEN-LABEL LONG-TERM EXTENSION
    Ferrante, Marc
    Panaccione, Remo
    Colombel, Jean Frederic
    Dubinsky, Marla C.
    Hisamatsu, Tadakazu
    Lindsay, James O.
    Song, Alexandra P.
    Neimark, Ezequiel
    Zhang, Ying
    Kligys, Kristina
    Crowley, Jameson
    Duan, W. Rachel
    D'Haens, Geert
    GASTROENTEROLOGY, 2024, 166 (05) : S801 - S802
  • [8] Long-term efficacy and safety of mirikizumab treatment for Crohn's Disease: Results from the VIVID-2 open-label extension study
    Vermeire, S.
    Sands, B. E.
    D'Haens, G.
    Hisamatsu, T.
    Kelly, C. R.
    Lu, N.
    Morris, N.
    Moses, R.
    Durand, F.
    Protic, M.
    Hozak, R. R.
    Lopes, M. U.
    Regueiro, M.
    Laharie, D.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i87 - i89
  • [9] Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease: Results From the One-Year SEQUENCE Open-Label Long-Term Extension
    Peyrin-Biroulet, L.
    Atreya, R.
    Danese, S.
    Lindsay, J. O.
    Chapman, J. C.
    Anschutz, T.
    Huang, X.
    Zambrano, J.
    Platt, A.
    Joshi, N.
    Cross, R. K.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1407 - i1409
  • [10] Long-term treatment with lumasiran: final results from the phase 2 open-label extension study
    Frishberg, Yaacov
    Groothoff, Jaap W.
    Hulton, Sally-Anne
    Harambat, Jerome
    Hogan, Julien
    Anne-Laure, Sellier-Leclerc
    Hayes, Wesley
    Coenen, Martin
    Willey, Richard
    Gansner, John
    Magen, Daniella
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
12345